Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €64.16 EUR
Change Today +0.51 / 0.80%
Volume 0.0
8AK On Other Exchanges
Symbol
Exchange
Frankfurt
As of 1:44 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for alkermes plc (8AK)

Year over year, Alkermes plc has seen their bottom line shrink from a gain of $20.6M USD to a loss of $30.1M USD despite an increase in revenues from $596.3M USD to $618.8M USD. An increase in the percentage of sales devoted to SGA costs from 27.22% to 33.42% was a key component in the falling bottom line in the face of rising revenues.
Currency in
Millions of US Dollars
As of:Mar 31
2011
Reclassified
Mar 31
2012
Reclassified
Dec 31
2013
Dec 31
2014
4 Year
Trend
Revenues186.6390.0596.3618.8
TOTAL REVENUES186.6390.0596.3618.8
Cost of Goods Sold52.2127.6176.9175.8
GROSS PROFIT134.5262.4419.4443.0
Selling General & Admin Expenses, Total87.7113.6162.3206.8
R&D Expenses91.2136.8152.8265.1
Depreciation & Amortization, Total--25.448.858.2
OTHER OPERATING EXPENSES, TOTAL179.0275.8363.9530.1
OPERATING INCOME-44.5-13.455.5-87.1
Interest Expense-3.3-28.1-21.9-13.4
Interest and Investment Income2.71.50.92.0
NET INTEREST EXPENSE-0.6-26.6-21.0-11.5
Currency Exchange Gains (Loss)--0.50.20.6
Other Non-Operating Income (Expenses)-0.30.0-0.4-2.8
EBT, EXCLUDING UNUSUAL ITEMS-45.4-39.534.3-100.8
Merger & Restructuring Charges-1.1-29.1-17.7--
Gain (Loss) on Sale of Investments------44.9
Gain (Loss) on Sale of Assets------41.9
Other Unusual Items, Total---45.8-3.3--
EBT, INCLUDING UNUSUAL ITEMS-46.5-114.413.3-14.0
Income Tax Expense-1.0-0.7-7.416.0
Earnings from Continuing Operations-45.5-113.720.6-30.1
NET INCOME-45.5-113.720.6-30.1
NET INCOME TO COMMON INCLUDING EXTRA ITEMS-45.5-113.720.6-30.1
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS-45.5-113.720.6-30.1
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8AK:GR €64.16 EUR +0.51

8AK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $30.80 USD -0.37
Incyte Corp $109.74 USD +5.76
Jazz Pharmaceuticals PLC $190.66 USD -2.11
Lupin Ltd 1,646 INR +5.05
Pacira Pharmaceuticals Inc/DE $64.96 USD +0.54
View Industry Companies
 

Industry Analysis

8AK

Industry Average

Valuation 8AK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.2x
Price/Book 7.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.